SESSION DESCRIPTION
This is a strong session of new therapies for Myelofibrosis and 1 for Mast cell disease. If other clinical MPN session has 1 MF oral trial could move it here, and swap out the SM trial to theirs if makes sense.<br /><br />Sugested Title: <span style="caret-color: #000000; color: #000000; font-family: Aptos, Aptos_EmbeddedFont, Aptos_MSFontService, Calibri, Helvetica, sans-serif; font-size: 14.666667px; font-style: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration: none; display: inline !important; float: none;">MF and SM: Emerging Targets and Treatment Strategies</span>
KEYWORDS
Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, MPN, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence